<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>First-line DLBCL &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/first-line-dlbcl/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 25 Jan 2026 14:45:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>First-line DLBCL &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>New Regimen Boosts DLBCL Treatment: BTK Inhibitors, Rituximab, Lenalidomide</title>
		<link>https://bioengineer.org/new-regimen-boosts-dlbcl-treatment-btk-inhibitors-rituximab-lenalidomide/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 25 Jan 2026 14:44:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[BTK inhibitör kombinasyonu]]></category>
		<category><![CDATA[BTK inhibitor treatment]]></category>
		<category><![CDATA[DLBCL combination therapy]]></category>
		<category><![CDATA[DLBCL tedavisi]]></category>
		<category><![CDATA[First-line DLBCL]]></category>
		<category><![CDATA[Innovative lymphoma therapies]]></category>
		<category><![CDATA[Retrospective lymphoma study]]></category>
		<category><![CDATA[Retrospektif çalışma **Açıklama:** 1. **DLBCL tedavisi:** Makalenin temel odağı olan hastalığı (Diffüz Büyük B-Hücreli Lenfoma) ve tedavi yaklaşımlarını do]]></category>
		<category><![CDATA[Rituximab-lenalidomide]]></category>
		<category><![CDATA[Yeni tanı DLBCL]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-regimen-boosts-dlbcl-treatment-btk-inhibitors-rituximab-lenalidomide/</guid>

					<description><![CDATA[In a significant leap in treating newly diagnosed diffuse large B-cell lymphoma (DLBCL), researchers have unveiled promising results from a retrospective study assessing the efficacy of a novel therapeutic regimen. This study, led by a team including Y. Lv, Y. Zhu, and C. Yang, shines a light on the potential benefits of combining a Bruton [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320718</post-id>	</item>
	</channel>
</rss>
